Cancer Research

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces clinical trial findings showing that trastuzumab (Herceptin) should remain the standard of care for this cancer.

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.

Within the first 5 years after the birth of a child, women are considered at an increased risk of developing metastatic breast cancer.

Why that happens has been considered a puzzle but the fact remains that women diagnosed with postpartum breast cancer have a decreased disease free survival time compared to women that have never given birth.

The aggressive tendency of postpartum breast cancer suggests that the post-birth breast environment promotes tumor metastasis. A new study in the Journal of Clinical Investigation, suggests that dying tumor cells in postpartum breast tissue promote metastatic disease.

Ovarian cancer is the most deadly gynecological kind, it claims the lives of more than 50% of women who are diagnosed

Ovarian cancer is often diagnosed late and develops a resistance to chemotherapy but new insight into why may lead to better diagnosis and treatment.

Retinoblastoma is a childhood retinal tumor usually affecting children ages one to two and the most common malignant tumor of the eye in children. Left untreated, retinoblastoma can be fatal or result in blindness.

Retinoblastomas have been found to develop in response to the mutation of a single gene, the RB1 gene, demonstrating that some cells are only a step away from developing into a life-threatening malignancy.

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort, according to two studies published in  OncoImmunology

Researchers from  at The Ohio State University Comprehensive Cancer Center identify new peptide vaccines and inhibitors that target the HER-3 and IGF-1R receptors. All four agents elicited significant anti-tumor responses in human cancer cell lines and in animal models. 

Head and neck cancer underway. Credit: Akira Kouchiyama, CC BY-SA

By Emma King, University of Southampton and Christian Ottensmeier, University of Southampton

An international research consortium has found that longer telomeres increase the risk of melanoma.

Men who had moderate baldness affecting both the front and the crown of their head by age 45 were at a 40% increased risk of developing aggressive prostate cancer than men with no baldness, according to a new, large cohort analysis from the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prostate cancer is the second most common cancer among men.
Aggressive prostate cancer usually indicates a faster growing tumor resulting in poorer prognosis relative to non-aggressive prostate cancer later in life. There was no significant link between other patterns of baldness and prostate cancer risk. 

The genetic mutation BRAFV600E secretes a protein that promotes the growth of melanoma tumor cells and modify the network of normal cells around the tumor to support the disease's progression, according to a new paper.

Targeting this mutation with Vemurafenib reduces this interaction, and suggests possible new treatment options for melanoma therapy. BRAFV600E is common present in metastatic melanoma.